;PMID: 7951583
;source_file_789.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:35..113] = [t:35..113]
;2)section:[e:117..195] = [t:117..195]
;3)section:[e:199..290] = [t:199..290]
;4)sentence:[e:294..419] = [t:294..419]
;5)sentence:[e:420..569] = [t:420..569]
;6)sentence:[e:570..648] = [t:570..648]
;7)sentence:[e:649..743] = [t:649..743]
;8)sentence:[e:744..935] = [t:744..935]
;9)sentence:[e:936..1024] = [t:936..1024]
;10)sentence:[e:1025..1115] = [t:1025..1115]
;11)sentence:[e:1116..1220] = [t:1116..1220]
;12)sentence:[e:1221..1337] = [t:1221..1337]
;13)section:[e:1341..1385] = [t:1341..1385]

;section 0 Span:0..30
;Endocr J  1994 Jun;41(3):301-8
(SEC
  (FRAG (NNP:[0..6] Endocr) (NNP:[7..8] J) (CD:[10..14] 1994)
        (CC:[15..22] Jun;41-LRB-) (CD:[22..23] 3) (-RRB-:[23..24] -RRB-)
        (CD:[24..28] :301) (::[28..29] -) (CD:[29..30] 8)))

;sentence 1 Span:35..113
;Specific PCR amplification for N-ras mutations in neoplastic thyroid
;diseases.
;[66..71]:gene-rna:"N-ras"
;[85..112]:malignancy:"neoplastic thyroid diseases"
(SENT
  (NP-HLN
    (NP (JJ:[35..43] Specific) (NN:[44..47] PCR) (NN:[48..61] amplification))
    (PP (IN:[62..65] for)
      (NP (NN:[66..71] N-ras) (NNS:[72..81] mutations)))
    (PP (IN:[82..84] in)
      (NP (JJ:[85..95] neoplastic) (JJ:[96..103] thyroid)
          (NNS:[104..112] diseases)))
    (.:[112..113] .)))

;section 2 Span:117..195
;Kaihara M, Taniyama M, Tadatomo J, Tobe T, Tomita M, Ito K, Ban Y, Katagiri
;T.
(SEC
  (FRAG (NNP:[117..124] Kaihara) (NNP:[125..127] M,) (NNP:[128..136] Taniyama)
        (NNP:[137..139] M,) (NNP:[140..148] Tadatomo) (NNP:[149..151] J,)
        (NNP:[152..156] Tobe) (NNP:[157..158] T) (,:[158..159] ,)
        (NNP:[160..166] Tomita) (NNP:[167..169] M,) (NNP:[170..173] Ito)
        (NNP:[174..175] K) (,:[175..176] ,) (NNP:[177..180] Ban)
        (NNP:[181..182] Y) (,:[182..183] ,) (NNP:[184..192] Katagiri)
        (NNP:[193..195] T.)))

;section 3 Span:199..290
;Third Department of Internal Medicine, School of Medicine, Showa University, 
;Tokyo, Japan.
(SEC
  (FRAG (NNP:[199..204] Third) (NNP:[205..215] Department) (IN:[216..218] of)
        (NNP:[219..227] Internal) (NNP:[228..236] Medicine) (,:[236..237] ,)
        (NNP:[238..244] School) (IN:[245..247] of) (NNP:[248..256] Medicine)
        (,:[256..257] ,) (NNP:[258..263] Showa) (NNP:[264..274] University)
        (,:[274..275] ,) (NNP:[277..282] Tokyo) (,:[282..283] ,)
        (NNP:[284..289] Japan) (.:[289..290] .)))

;sentence 4 Span:294..419
;We analyzed point mutations of N-ras protooncogene codon 61 in thyroid
;neoplasms  by means of a mutation-specific PCR method.
;[306..321]:variation-type:"point mutations"
;[325..330]:gene-rna:"N-ras"
;[345..353]:variation-location:"codon 61"
(SENT
  (S
    (NP-SBJ (PRP:[294..296] We))
    (VP (VBD:[297..305] analyzed)
      (NP
        (NP (NN:[306..311] point) (NNS:[312..321] mutations))
        (PP (IN:[322..324] of)
          (NP
            (NML (NN:[325..330] N-ras) (NN:[331..344] protooncogene))
             (NN:[345..350] codon) (CD:[351..353] 61))))
      (PP-LOC (IN:[354..356] in)
        (NP (JJ:[357..364] thyroid) (NNS:[365..374] neoplasms)))
      (PP-MNR (IN:[376..378] by)
        (NP
          (NP (NNS:[379..384] means))
          (PP (IN:[385..387] of)
            (NP (DT:[388..389] a)
              (ADJP (NN:[390..398] mutation) (HYPH:[398..399] -)
                    (JJ:[399..407] specific))
              (NN:[408..411] PCR) (NN:[412..418] method))))))
    (.:[418..419] .)))

;sentence 5 Span:420..569
;In this method, one of the paired  primers has a base at the 3' terminal that
;is complementary to a mutated base of  the DNA sequence to be analyzed.
(SENT
  (S
    (PP (IN:[420..422] In)
      (NP (DT:[423..427] this) (NN:[428..434] method)))
    (,:[434..435] ,)
    (NP-SBJ
      (NP (CD:[436..439] one))
      (PP (IN:[440..442] of)
        (NP (DT:[443..446] the) (JJ:[447..453] paired) (NNS:[455..462] primers))))
    (VP (VBZ:[463..466] has)
      (NP
        (NP
          (NP (DT:[467..468] a) (NN:[469..473] base))
          (PP-LOC (IN:[474..476] at)
            (NP (DT:[477..480] the) (CD:[481..483] 3') (NN:[484..492] terminal))))
        (SBAR
          (WHNP-1 (WDT:[493..497] that))
          (S
            (NP-SBJ-1 (-NONE-:[497..497] *T*))
            (VP (VBZ:[498..500] is)
              (ADJP-PRD (JJ:[501..514] complementary)
                (PP (TO:[515..517] to)
                  (NP
                    (NP (DT:[518..519] a) (JJ:[520..527] mutated)
                        (NN:[528..532] base))
                    (PP (IN:[533..535] of)
                      (NP
                        (NP (DT:[537..540] the) (NN:[541..544] DNA)
                            (NN:[545..553] sequence))
                        (SBAR
                          (WHNP-2 (-NONE-:[553..553] 0))
                          (S
                            (NP-SBJ-2 (-NONE-:[553..553] *T*))
                            (VP (TO:[554..556] to)
                              (VP (VB:[557..559] be)
                                (VP (VBN:[560..568] analyzed)
                                  (NP-2 (-NONE-:[568..568] *)))))))))))))))))
    (.:[568..569] .)))

;sentence 6 Span:570..648
;With this primer, only alleles which have the  same mutation can be
;amplified.
;[622..630]:variation-event:"mutation"
(SENT
  (S
    (PP (IN:[570..574] With)
      (NP (DT:[575..579] this) (NN:[580..586] primer)))
    (,:[586..587] ,)
    (NP-SBJ-2
      (NP (RB:[588..592] only) (NNS:[593..600] alleles))
      (SBAR
        (WHNP-1 (WDT:[601..606] which))
        (S
          (NP-SBJ-1 (-NONE-:[606..606] *T*))
          (VP (VBP:[607..611] have)
            (NP (DT:[612..615] the) (JJ:[617..621] same)
                (NN:[622..630] mutation))))))
    (VP (MD:[631..634] can)
      (VP (VB:[635..637] be)
        (VP (VBN:[638..647] amplified)
          (NP-2 (-NONE-:[647..647] *)))))
    (.:[647..648] .)))

;sentence 7 Span:649..743
;Among 24 thyroid tissues, we detected 2 point  mutations out of 7 follicular
;carcinomas (29%).
;[689..705]:variation-type:"point  mutations"
;[715..736]:malignancy:"follicular carcinomas"
(SENT
  (S
    (PP (IN:[649..654] Among)
      (NP (CD:[655..657] 24) (JJ:[658..665] thyroid) (NNS:[666..673] tissues)))
    (,:[673..674] ,)
    (NP-SBJ (PRP:[675..677] we))
    (VP (VBD:[678..686] detected)
      (NP
        (NP (CD:[687..688] 2)
           (NN:[689..694] point) (NNS:[696..705] mutations))
        (PP (IN:[706..709] out)
          (PP (IN:[710..712] of)
            (NP (CD:[713..714] 7)
               (JJ:[715..725] follicular) (NNS:[726..736] carcinomas))))
        (PRN (-LRB-:[737..738] -LRB-)
          (NP (CD:[738..740] 29) (NN:[740..741] %))
          (-RRB-:[741..742] -RRB-))))
    (.:[742..743] .)))

;sentence 8 Span:744..935
;One tumor had a cytosine to  adenine substitution mutation at the first base
;of codon 61, and the other had  an adenine to guanine substitution mutation
;in the second base of the same  codon.
;[748..753]:malignancy:"tumor"
;[760..768]:variation-state-original:"cytosine"
;[773..780]:variation-state-altered:"adenine"
;[781..793]:variation-type:"substitution"
;[794..802]:variation-event:"mutation"
;[810..832]:variation-location:"first base of codon 61"
;[856..863]:variation-state-original:"adenine"
;[867..874]:variation-state-altered:"guanine"
;[875..887]:variation-type:"substitution"
;[888..896]:variation-event:"mutation"
;[904..934]:variation-location:"second base of the same  codon"
(SENT
  (S
    (S
      (NP-SBJ (CD:[744..747] One) (NN:[748..753] tumor))
      (VP (VBD:[754..757] had)
        (NP
          (NP (DT:[758..759] a)
            (NML
              (NML
                (NML (NN:[760..768] cytosine))
                (PP (TO:[769..771] to)
                  (NP (NN:[773..780] adenine))))
              (NN:[781..793] substitution))
            (NN:[794..802] mutation))
          (PP-LOC (IN:[803..805] at)
            (NP
              (NP (DT:[806..809] the) (JJ:[810..815] first) (NN:[816..820] base))
              (PP (IN:[821..823] of)
                (NP (NN:[824..829] codon) (CD:[830..832] 61))))))))
    (,:[832..833] ,) (CC:[834..837] and)
    (S
      (NP-SBJ (DT:[838..841] the) (NN:[842..847] other))
      (VP (VBD:[848..851] had)
        (NP
          (NP (DT:[853..855] an)
            (NML
              (NML
                (NML (NN:[856..863] adenine))
                (PP (TO:[864..866] to)
                  (NP (NN:[867..874] guanine))))
              (NN:[875..887] substitution))
            (NN:[888..896] mutation))
          (PP-LOC (IN:[897..899] in)
            (NP (DT:[900..903] the)
              (NML
                (NML (JJ:[904..910] second) (NN:[911..915] base))
                (PP (IN:[916..918] of)
                  (NP (DT:[919..922] the) (JJ:[923..927] same)
                      (NN:[929..934] codon)))))))))
    (.:[934..935] .)))

;sentence 9 Span:936..1024
;The same mutations were not detected in 7 follicular adenomas or 1  papillary
;carcinoma.
;[945..954]:variation-event:"mutations"
;[978..997]:malignancy:"follicular adenomas"
;[1004..1023]:malignancy:"papillary carcinoma"
(SENT
  (S
    (NP-SBJ-1 (DT:[936..939] The) (JJ:[940..944] same)
              (NNS:[945..954] mutations))
    (VP (VBD:[955..959] were) (RB:[960..963] not)
      (VP (VBN:[964..972] detected)
        (NP-1 (-NONE-:[972..972] *))
        (PP-LOC (IN:[973..975] in)
          (NP
            (NP (CD:[976..977] 7)
               (JJ:[978..988] follicular) (NNS:[989..997] adenomas))
            (CC:[998..1000] or)
            (NP (CD:[1001..1002] 1)
               (JJ:[1004..1013] papillary) (NN:[1014..1023] carcinoma))))))
    (.:[1023..1024] .)))

;sentence 10 Span:1025..1115
;These results were confirmed by both dot blot hybridization  and direct
;sequencing method.
(SENT
  (S
    (NP-SBJ-1 (DT:[1025..1030] These) (NNS:[1031..1038] results))
    (VP (VBD:[1039..1043] were)
      (VP (VBN:[1044..1053] confirmed)
        (NP-1 (-NONE-:[1053..1053] *))
        (PP-MNR (IN:[1054..1056] by)
          (NP (CC:[1057..1061] both)
            (NP
              (NML (NN:[1062..1065] dot) (NN:[1066..1070] blot))
              (NN:[1071..1084] hybridization))
            (CC:[1086..1089] and)
            (NP
              (NML (JJ:[1090..1096] direct) (NN:[1097..1107] sequencing))
              (NN:[1108..1114] method))))))
    (.:[1114..1115] .)))

;sentence 11 Span:1116..1220
;Mutation of N-ras codon 61 may be significant in  malignant transformation of
;follicular thyroid tumors.
;[1116..1124]:variation-event:"Mutation"
;[1128..1133]:gene-rna:"N-ras"
;[1134..1142]:variation-location:"codon 61"
;[1194..1219]:malignancy:"follicular thyroid tumors"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1116..1124] Mutation))
      (PP (IN:[1125..1127] of)
        (NP (NN:[1128..1133] N-ras)
           (NN:[1134..1139] codon) (CD:[1140..1142] 61))))
    (VP (MD:[1143..1146] may)
      (VP (VB:[1147..1149] be)
        (ADJP-PRD (JJ:[1150..1161] significant))
        (PP (IN:[1162..1164] in)
          (NP
            (NP (JJ:[1166..1175] malignant) (NN:[1176..1190] transformation))
            (PP (IN:[1191..1193] of)
              (NP (JJ:[1194..1204] follicular) (JJ:[1205..1212] thyroid)
                  (NNS:[1213..1219] tumors)))))))
    (.:[1219..1220] .)))

;sentence 12 Span:1221..1337
;Because of its easy  availability, the mutation-specific PCR method is a
;useful screening test for  N-ras mutations.
;[1321..1326]:gene-rna:"N-ras"
(SENT
  (S
    (PP (IN:[1221..1228] Because)
      (PP (IN:[1229..1231] of)
        (NP (PRP$:[1232..1235] its) (JJ:[1236..1240] easy)
            (NN:[1242..1254] availability))))
    (,:[1254..1255] ,)
    (NP-SBJ (DT:[1256..1259] the)
      (ADJP (NN:[1260..1268] mutation) (HYPH:[1268..1269] -)
            (JJ:[1269..1277] specific))
      (NN:[1278..1281] PCR) (NN:[1282..1288] method))
    (VP (VBZ:[1289..1291] is)
      (NP-PRD
        (NP (DT:[1292..1293] a) (JJ:[1294..1300] useful)
            (NN:[1301..1310] screening) (NN:[1311..1315] test))
        (PP (IN:[1316..1319] for)
          (NP (NN:[1321..1326] N-ras) (NNS:[1327..1336] mutations)))))
    (.:[1336..1337] .)))

;section 13 Span:1341..1385
;PMID: 7951583 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1341..1345] PMID) (::[1345..1346] :) (CD:[1347..1354] 7951583)
        (NN:[1355..1356] -LSB-) (NNP:[1356..1362] PubMed) (::[1363..1364] -)
        (NN:[1365..1372] indexed) (IN:[1373..1376] for)
        (NNP:[1377..1385] MEDLINE-RSB-)))
